📋 Clinical Overview

Clofazimine is a riminophenazine dye derivative with potent anti-mycobacterial and anti-inflammatory properties. It is a cornerstone in the treatment of leprosy (Hansen's disease) and is increasingly used for drug-resistant tuberculosis (DR-TB) in India. It is a lipophilic, crystalline dye that accumulates in macrophages and adipose tissue, leading to a long half-life and characteristic skin pigmentation.

💊 Dosage & Administration

Adult: **Leprosy (MDT):** 50 mg daily unsupervised + 300 mg once monthly supervised. **ENL Reaction:** 100-300 mg daily for up to 12 weeks, tapered to 100 mg daily. **DR-TB (NTEP India):** 100 mg once daily as part of longer regimens (e.g., 18-20 month regimen) or 100 mg daily as part of shorter BPaL/M regimen (Bedaquiline, Pretomanid, Linezolid, Moxifloxacin).

Note: Administer with meals, preferably a fatty meal, to enhance absorption. Capsule should be swallowed whole with water. Do not crush or chew. To improve adherence for skin discoloration, counsel patients thoroughly. For monthly supervised doses in leprosy MDT, administer under direct observation.

⚠️ Contraindications

Known hypersensitivity to clofazimine or any component of the formulation
Patients with severe hepatic impairment or acute liver disease (due to risk of accumulation and hepatotoxicity)
Patients with severe abdominal pain or diarrhea, especially if related to previous clofazimine use (risk of enteropathy).

🔬 Mechanism of Action

Clofazimine's exact mechanism is multifactorial. Its primary action is believed to be through binding to mycobacterial guanine bases in DNA, inhibiting template function and replication. It also has a high affinity for mycobacterial DNA, causing growth inhibition. Additionally, it possesses potent anti-inflammatory effects by stabilizing lysosomal membranes and inhibiting neutrophil migration and T-cell proliferation, which is crucial for managing leprosy reactions.

🤕 Side Effects

Reddish-brown to blackish skin pigmentation (nearly 100% with prolonged use)
Dry skin, ichthyosis, and pruritus
Discoloration of urine, sweat, tears, sputum, and conjunctivae
Nausea, vomiting, abdominal pain
Diarrhea (usually mild)

🤰 Special Populations

Pregnancy: Category C (US FDA). Animal studies show fetal harm. No adequate human studies. Use only if the potential benefit justifies the potential risk to the fetus (e.g., for life-threatening DR-TB). Skin discoloration of the newborn is possible.

Driving: Generally safe. However, may cause dizziness or visual disturbances in some patients. Caution advised until individual response is known.

🔄 Drug Interactions

QT-prolonging drugs (e.g., Fluoroquinolones like Moxifloxacin, Macrolides, Antiarrhythmics)	Additive risk of QTc prolongation, leading to Torsades de Pointes.	Major
Rifampicin	Rifampicin may decrease clofazimine levels by inducing metabolism, potentially reducing efficacy. This is managed in MDT by giving higher monthly supervised doses.	Moderate
Isoniazid	May increase risk of hepatotoxicity. Monitor LFTs closely.	Moderate
Bedaquiline	Both can prolong QTc interval. Requires mandatory ECG monitoring before and during therapy as per NTEP guidelines.	Major
Antacids/Aluminum salts	May decrease absorption of clofazimine. Administer at least 2 hours apart.	Minor

Hanzol